ESPID Education. Antachopoulos C. 05/10/12; 20826 Disclosure(s)(s): Nothing to disclose
Dr. Charalampos Antachopoulos
Dr. Charalampos Antachopoulos

This content is available to ESPID members only

Click here for more information or if you are considering becoming an ESPID member.

Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
-Understand the mechanisms of action, in vitro activity and important lessons learned from adult studies regarding the following agents currently used for treatment of infections caused by multidrug-resistant Gram-negative bacteria: colistin, tigecyclin and fosfomycin

-Summarize pharmacokinetic, safety and efficacy data available for pediatric patients

-Identify gaps of knowledge and areas for future research in order to optimize use in pediatric population
The emergence of infections caused by multi-resistant Gram-negative bacteria over the last years has been associated with increased morbidity and mortality both in adult and pediatric patients. As these infections are often resistant to many classes of conventional antimicrobial agents (including the carbapenems and aminoglycosides) the remaining therapeutic options likely to be effective are limited. A number of antimicrobial compounds active against these bacteria have been lately introduced, such as tigecycline, whereas others, already known for decades, have been
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies